

A Beginner's Guide To Cancer Immunotherapy

Virtual study day

9th June 2022

Aims:

In this half-day course, Dr Elaine Vickers will equip learners with the scientific concepts, language, and knowledge that healthcare professionals need in order to discuss immunotherapies with their patients and colleagues.

Dr Vickers' goal is to explain the science that underpins immunotherapy. She also hopes to provide learners with a broad understanding of why it works well for some patients but not for others.

Elaine's presentations are full of colourful and enlightening illustrations to help learners make sense of scientific concepts. Her descriptions avoid unnecessary jargon and are pitched so that even those with a limited understanding of cell biology and immunology are able to understand.

Audience:

This content is ideal for research nurses, clinical nurse specialists, pharmacists and clinical trials coordinators. It may also be of interest to other healthcare professionals who would like to improve their understanding of immunotherapy.

Cost:

£50 per day

Register:

<https://www.royalmarsden.nhs.uk/beginners-guide-to-cancer-immunotherapy>

Get in touch:

Conferenceteam@rmh.nhs.uk

020 7808 2921

Follow us:



Sponsors:



Programme :

- 10:00 • **Welcome & Introductions**
- 10:10 • **Session 1 – The relationship between cancer and the immune system**
 - • A brief introduction to the immune system
 - • How cancer's relationship with the immune system changes over time
 - • How the immune system can recognise and react to the presence of cancer in the body
 - • How cancer cells avoid being destroyed by white blood cells
 - • Introduction to immunotherapy and the importance of T cells
 - • Reasons why immunotherapy sometimes does work and sometimes doesn't
- 10:45 • **LIVE Q&A**
- 10:55 • **Break/Sponsor Exhibition**
- 11:00 • **Session 2 – Immunotherapy with checkpoint inhibitors for solid tumours**
 - • Introduction to checkpoint proteins on T cells
 - • Mechanism of action of checkpoint inhibitors that target PD-1, PD-L1 and CTLA-4
 - • Progress so far with checkpoint inhibitors
 - • Checkpoint inhibitor combinations
 - • Biomarkers to select patients most likely to respond
- 11:35 • **LIVE Q&A**
- 11:45 • **Break/Sponsor Exhibition**
- 11:50 • **Session 3 – Immunotherapy for haematological cancers**
 - • Targeting CD antigens on T cells with monoclonal antibodies
 - • Tethering cancer cells to T cells: bi-specific antibodies & bi-specific T cell engagers
 - • CAR T cell therapy:
 - • Overview of the CAR T cell process
 - • CAR protein design – what each bit does and why it matters
 - • Reasons for resistance and relapse
 - • Overview of the results so far with CAR T cells for different haematological cancers
- 12:25 • **LIVE Q&A**

Please note that the content will be available online after the event.